Levosert One

Levonorgestrel, the active ingredient in Levosert One, is a progestin presented as a 20 µg/day release intrauterine system for intrauterine use. It provides long‑acting reversible contraception for women of reproductive age.

GNH USA supplies Levosert One as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosert One, a levonorgestrel‑based intrauterine system, is indicated for hormonal contraception.

- Contraception: provides up to five years of reliable pregnancy prevention. - Heavy menstrual bleeding: may reduce menstrual blood loss and the need for additional therapy. - Dysmenorrhea: can lessen menstrual pain associated with prostaglandin‑mediated cramps.

Levosert One may be associated with a range of adverse reactions.

Common Side Effects: - Irregular vaginal bleeding or spotting. - Amenorrhea (absence of periods). - Cramping or pelvic discomfort after insertion. - Insertion‑related pain. - Hormonal changes such as breast tenderness. - Headache or mild nausea.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion or displacement of the device. - Pelvic inflammatory disease or severe infection. - Ectopic pregnancy if contraception fails. - Device migration to adjacent organs. - Severe allergic reaction to device components.

Prior to insertion, clinicians should assess patient suitability and counsel on potential risks.

- Pregnancy screening: confirm the patient is not pregnant before placement. - Uterine anomalies: avoid use in women with known congenital uterine malformations. - Active infection: contraindicated in the presence of pelvic inflammatory disease or genital infections. - Malignancy: not recommended for patients with estrogen‑dependent cancers. - Follow‑up: schedule a post‑insertion check to verify correct positioning. - Storage: Store at below 25 °C: keep in the original packaging, protect from moisture and direct sunlight.

Levonorgestrel released from an intrauterine system can be affected by certain concomitant medicines.

Major Interactions (Avoid): - Rifampicin, carbamazepine, phenytoin, or St. John’s wort: potent enzyme inducers that may lower levonorgestrel levels. - Antiretroviral efavirenz: may reduce contraceptive efficacy. - High‑dose enzyme‑inducing anticonvulsants: can compromise hormonal protection.

Moderate Interactions (Monitor Closely): - Ketoconazole or other azole antifungals: may increase levonorgestrel exposure. - Phenobarbital: moderate enzyme induction requiring monitoring. - Certain herbal supplements (e.g., ginseng): may alter hormone metabolism.